CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD

Ermann N, Lewczuk P, Schmitz M, Lange P, Knipper T, Goebel S, Kornhuber J, Zerr I, Llorens F (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Annals of Clinical and Translational Neurology Wiley

Book Volume: 5

Pages Range: 883-887

Journal Issue: 7

DOI: 10.1002/acn3.584

Abstract

Creutzfeldt-Jakob disease and Alzheimer's disease are characterized by the presence of elevated total-Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho-Tau epitopes (non-P-Tau) in the discrimination between both diseases. Non-P-Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt-Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total-Tau (90%), P-Tau (62%) and 14-3-3 (91%).

Authors with CRIS profile

Natalia Ermann Medizinische Fakultät Piotr Lewczuk Department of Psychiatry and Psychotherapy Johannes Kornhuber Lehrstuhl für Psychiatrie und Psychotherapie

Involved external institutions

Universitätsklinikum Göttingen DE Germany (DE)

How to cite

APA:

Ermann, N., Lewczuk, P., Schmitz, M., Lange, P., Knipper, T., Goebel, S.,... Llorens, F. (2018). CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD. Annals of Clinical and Translational Neurology, 5(7), 883-887. https://doi.org/10.1002/acn3.584

MLA:

Ermann, Natalia, et al. "CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD." Annals of Clinical and Translational Neurology 5.7 (2018): 883-887.

BibTeX: Download